Clinical prognostic factors in progressive supranuclear palsy: Implications for clinical trials
PSP-RS has a less favorable prognosis compared to PSP variants stratified according to the MDS-PSP classification. This classification could assist in selecting patients for clinical trials and help design outcomes that account for the disease heterogeneity.
Authors
- Anne-Sophie Blaise (ORCID: https://orcid.org/0000-0002-1731-3009)
- David Devos (ORCID: https://orcid.org/0000-0002-2417-799X)
- Félix Marchand (ORCID: https://orcid.org/0000-0002-3218-5092)
- Stéphanie Bombois (ORCID: https://orcid.org/0000-0003-3117-1833)
- Caroline Moreau (ORCID: https://orcid.org/0000-0002-5683-2709)
- Émeline Cailliau (ORCID: https://orcid.org/0000-0001-5343-6471)
- Luc Defebvre
Institutions
- Inserm (FR)
- Université de Lille (FR)
- Centre Hospitalier Universitaire de Lille (FR)
- Lille’s Cardiology Hospital (FR)
- Lille Neurosciences & Cognition (FR)
Publication Details
- Journal
- Journal of Parkinson s Disease
- Published
- 2024-11-01
- DOI
- https://doi.org/10.1177/1877718x241291996
- Citations
- 1
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.37